Related Experiment Video
Updated: Nov 3, 2025
Mouse Bladder Wall Injection
Published on: July 12, 2011
Fascin Inhibitors Decrease Cell Migration and Adhesion While Increase Overall Survival of Mice Bearing Bladder
Zhankui Zhao1, Yufeng Wang1, J Jillian Zhang2
1Department of Physiology and Biophysics, Weill Cornell Medical College of Cornell University, New York, NY 10065, USA.
Abstract:
Bladder cancer is one of the most common cancers in the world. Early stage bladder tumors can be surgically removed, but these patients usually have relapses. When bladder cancer becomes metastatic, survival is very low. There is an urgent need for new treatments for metastatic bladder cancers. Here, we report that a new fascin inhibitor decreases the migration and adhesion of bladder cancer cells. Furthermore, this inhibitor decreases the primary tumor growth and increases the overall survival of mice bearing bladder cancers, alone, as well as in combination with the chemotherapy medication, cisplatin, or the immune checkpoint inhibitor, anti-PD-1 antibody. These data suggest that fascin inhibitors can be explored as a new treatment for bladder cancers.
Insights
A novel fascin inhibitor shows promise for treating metastatic bladder cancer by reducing tumor growth and improving survival in mice. This compound may offer a new therapeutic option for patients with advanced bladder cancer.
Area of Science:
- Oncology
- Cancer Biology
- Pharmacology
Background:
- Bladder cancer is a prevalent malignancy with high recurrence rates after surgery.
- Metastatic bladder cancer has a poor prognosis, highlighting the need for novel therapeutic strategies.
- Fascin is an actin-bundling protein implicated in cancer cell migration and invasion.
Purpose of the Study:
- To investigate the therapeutic potential of a novel fascin inhibitor in bladder cancer.
- To evaluate the efficacy of the fascin inhibitor in preclinical models of bladder cancer.
Main Methods:
- In vitro assessment of bladder cancer cell migration and adhesion.
- In vivo studies using mouse models of bladder cancer to evaluate tumor growth and survival.
- Combination therapy studies with cisplatin and anti-PD-1 antibody.
Main Results:
- The fascin inhibitor significantly reduced bladder cancer cell migration and adhesion in vitro.
- In vivo, the inhibitor decreased primary tumor growth and prolonged overall survival in mice.
- Combination therapy with cisplatin or anti-PD-1 antibody demonstrated enhanced efficacy.
Conclusions:
- Fascin inhibitors represent a promising new class of drugs for bladder cancer treatment.
- This novel fascin inhibitor warrants further clinical investigation for metastatic bladder cancer.
- Combination strategies may enhance the effectiveness of fascin inhibitors in bladder cancer therapy.
Related Concept Videos
01:35Cancer Cell Migration through Invadopodia
01:17Intracellular Signaling Affects Focal Adhesions
Some...